$3.04
-0.07 (-2.25%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CLLS is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
6 interventional
Held by 1 tracked-famous manager (SUSQUEHANNA INTERNATIONAL GROUP, LLP) · FINRA short interest 22.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Study Evaluating UCART20x22 in B-Cell Non-Hodgkin LymphomaNCT05607420Dose finding and expansion parts: Incidence of adverse events/serious adverse events/dose limiting toxicity [Safety and Tolerability]Open-label · Treatment | Phase 1/2 | Recruiting | Biological: UCART20x22, CLLS52 | B-cell Non-Hodgkin Lymphoma (B-NHL) | 80 | Aug 2027 | ≤ 377 d | 2025-08-24 |
| Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)NCT04150497Incidence of AE/SAE/DLT [Safety and Tolerability]Open-label · Treatment | Phase 1/2 | Recruiting | Biological: UCART22, CLLS52 | B-cell Acute Lymphoblastic Leukemia | 52 | 2026-06-30 | — | 2025-09-09 |
| Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid LeukemiaNCT03190278Incidence of adverse events (AE)/serious adverse events (SAE)/Dose Limiting Toxicities (DLT) [Safety and Tolerability]Open-label · Treatment | Phase 1 | Active, not recruiting | Biological: UCART123v1.2 | Relapsed/Refractory Acute Myeloid Leukemia | 29 | 2024-12-24actual | — | 2025-08-07 |
| Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)NCT04142619Safety of UCARTCS1AOpen-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was discontinued due to sponsor's decision and not a consequence of any safety concern. | Biological: UCARTCS1A | Relapsed/Refractory Multiple Myeloma | 11 | 2023-06-18actual | — | 2023-09-22 |
| Phase I Study of UCART123 in Patient With Adverse Genetic Risk Acute Myeloid LeukemiaNCT04106076Incidence of AE/SAE/DLT [Safety and Tolerability]Open-label · Treatment | Phase 1 | Withdrawnsponsor's stated reason: The trial was discontinued due to sponsor's decision and not a consequence of any safety concern | Biological: UCART123 | Acute Myeloid Leukaemia | 0 | 2019-12-05actual | — | 2020-07-14 |
| Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCNNCT03203369Incidence, nature, and severity of adverse events and serious adverse eventsNon-randomized · Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: The trial was discontinued due to sponsor's decision and not a consequence of any safety concern. | Biological: UCART123 | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) | 1 | 2019-06-27actual | — | 2019-07-31 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19